TrialRopidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
Trial details
- Registry ID
- NCT06359379
- Phase
- Phase 2
SHPH
Shuttle Pharmaceuticals, Inc.
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
1Trials in this database
5Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT PromoterNCT06359379 | Shuttle Pharmaceuticals, Inc. | Phase 2 | Terminated | 2025-12-01Actual |
Latest recorded trial changes
Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
NCT06359379 · Shuttle Pharmaceuticals, Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
54 participants (planned)
+ After
30 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Aug 2026
+ After
1 Dec 2025
Recruitment status changed
− Before
Recruiting
+ After
Terminated